Dyne Therapeutics (DYN) Earnings Date
The next earnings date for Dyne Therapeutics (DYN) is expected by Feb 3, 2027, per the data provider's calendar.
- Next earnings date
- Feb 3, 2027
- expected by · quarter ending Dec '26
- Consensus EPS
- −1.00
- Dec '26 quarter · 9 analysts
- Consensus revenue
- 0.00
- Dec '26 quarter
- Latest stored quarter
- EPS −1.06
- revenue $0.00 · reported Nov 5, 2026
Does this company deliver against its own promises? Earnings are a check on the thesis, not a catalyst to chase.
Estimate-vs-actual scoring began Jul 2026, the Feb 3, 2027 report is the first we'll score. Earlier quarters predate our snapshots, so their surprise stays "—". We never backfill an estimate we didn't observe.
| Report | Est EPS | Act EPS | Est rev | Act rev | Reaction |
|---|---|---|---|---|---|
| Nov 5, 20268-K, before open · 7:30 am ET | −0.91 | −1.06 | 0.00 | $0.00 | −6.4%release day |
| Jul 29, 20268-K, after close · 4:35 pm ET | −0.75 | −1.08 | 0.00 | $0.00 | +2.5%next session |
| May 11, 20268-K, before open · 7:35 am ET | — | −0.73 | — | $0.00 | +4.8%release day |
| Jan 12, 20268-K, before open · 7:35 am ET | — | −0.69 | — | — | −1.7%release day |
| Nov 5, 20258-K, after close · 4:16 pm ET | — | −0.76 | — | $0.00 | −12.9%next session |
| Jul 28, 20258-K, after close · 4:15 pm ET | — | −0.97 | — | $0.00 | −1.2%next session |
| May 8, 20258-K, before open · 7:35 am ET | — | −1.05 | — | $0.00 | +20.2%release day |
| Jan 10, 20258-K, before open · 6:56 am ET | — | −0.90 | — | — | −31.1%release day |
Estimates for this company are reported in its local currency, while the annual actuals behind the fiscal-year figures are in US dollars. A year-ago figure and the estimate beside it would be two different currencies there, so we withhold those cells rather than publish a comparison that is not like for like. Where a year-ago figure is still shown, it is on the same local-currency basis as the estimate beside it, not a dollar one. The estimate rows are the provider's own figures, unconverted.
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 9 | 5 | 10 | 13 |
| Avg estimate | −1.00 | −1.01 | −3.82 | −3.70 |
| Low estimate | −1.19 | −1.08 | −3.97 | −4.48 |
| High estimate | −0.67 | −0.91 | −3.15 | −2.80 |
| Year-ago EPS | −0.69 | −0.73 | — | −3.82E |
| Implied growth | — | — | — | — |
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 0 | 5 | 9 | 12 |
| Avg estimate | 0.00 | 2.8M | 995,727.00 | 44.2M |
| Low estimate | 0.00 | 1.5M | 372,873.00 | 9.0M |
| High estimate | 0.00 | 6.8M | 2.8M | 97.4M |
| Year-ago revenue | — | 0.00 | — | 995,727.00E |
| Implied growth | — | — | — | +4339.4% |
| Snapshot age | Dec '26, period ending Dec 30, 2026 | Mar '27, period ending Mar 30, 2027 | FY26, period ending Dec 31, 2026 | FY27, period ending Dec 31, 2027 |
|---|---|---|---|---|
| Current estimate | −1.00 | −1.01 | −3.82 | −3.70 |
| 7 days ago | −1.00 | — | −3.82 | −3.70 |
| 30 days ago | −0.91 | — | −3.63 | −3.35 |
| 60 days ago | −0.90 | — | −3.61 | −3.35 |
| 90 days ago | −0.88 | — | −3.56 | −3.35 |
Estimate history accrues from our nightly snapshots. The 7/30/60/90-day rows fill in as tracking continues. Each column follows one fiscal period back through our snapshots; a dash means we had not recorded that period at that age. A rising bar makes a beat streak more meaningful; a falling one manufactures beats.
Dec '26 quarter consensus moved −0.88 → −1.00 over 90 tracked days, the same quarter at both ends. Per-analyst up/down revision counts aren't in our data feed. We show the bar's actual movement instead of guessing.
Common questions
When does Dyne Therapeutics report earnings next?
Dyne Therapeutics' next earnings date is expected by Feb 3, 2027, per the data provider's calendar.
What were Dyne Therapeutics' latest quarterly earnings?
Dyne Therapeutics reported diluted EPS of −1.06 and revenue of $0.00 on Nov 5, 2026.
How did Dyne Therapeutics' stock move after its last earnings report?
Dyne Therapeutics moved −6.4% in the session after its Nov 5, 2026 report.

